Eli Lilly and Company (LLY) fair value analysis

S&P 500 · Updated 2026-09-07

Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and sells medications for various therapeutic areas including oncology, immunology, endocrinology, and neuroscience. The company operates globally with operations and presence across multiple continents including North America, Europe, Asia, and other regions worldwide.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, LLY is trading at more than a 25% discount to estimated fair value.

LLY currently ranks #11 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $1,149.36
Sector: Healthcare
12-month range: $862.86–$1,160.00

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: High
Margin trend: Expanding
Revenue growth: High
RSI zone: Neutral
52-week position: The top quarter of its range

What our data shows for LLY

Our model validated 16 trailing price-to-earnings windows for LLY, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $862.86–$1,160.00.
The 14-day relative strength index sits at a neutral 45.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for LLY
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent LLY news

TickrTrends' derived news-sentiment signal for LLY is currently leaning positive, computed from recent coverage.

Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly? (insidermonkey.com, 2026-09-08)
TickrTrends take: Mounjaro's emerging cardiovascular benefits could expand the drug's addressable market beyond diabetes treatment, potentially supporting higher revenue projections that may justify premium valuations for Lilly. Given TickrTrends' current undervalued assessment, investors should monitor clinical trial outcomes and regulatory approval timelines for heart-related indications, as successful expansion could narrow or eliminate any valuation discount. The development represents a key catalyst that could materially shift growth expectations for the Healthcare sector company.
Lilly Launches Foundayo in the UK as NICE Review Continues (insidermonkey.com, 2026-09-05)
TickrTrends take: Lilly's UK launch of Foundayo while NICE conducts its review introduces timing considerations for European revenue recognition that investors focused on valuation should monitor closely. The regulatory pathway in the UK market could influence the company's ability to capture near-term sales in a major developed market, which bears relevance to current earnings projections underlying the Undervalued assessment. Given Healthcare sector cyclicality and the dependency of valuations on successful product commercialization, the NICE determination will be a key datapoint for validating whether the current valuation thesis holds or requires recalibration.
Could Roche and Lilly’s Blood Test Make Alzheimer’s Assessment More Accessible? (insidermonkey.com, 2026-09-05)
TickrTrends take: Eli Lilly and Roche's collaborative work on blood-based Alzheimer's diagnostics represents a potential expansion of the company's addressable market in neurodegenerative disease, which could support long-term revenue growth in the Healthcare sector. Given TickrTrends' current undervalued assessment of LLY, developments that improve diagnostic accessibility and patient identification may enhance the commercial potential of the company's pipeline therapies targeting Alzheimer's disease. Investors monitoring the stock's valuation should track how this diagnostic advancement translates into clinical adoption and revenue contribution over time.

What people are saying

Follow the LLY conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # LLY Weekly Summary TickrTrends' derived indicators for LLY showed notable movement this week as the momentum indicator downgraded from a B rating to none, suggesting a weakening in price momentum for the Healthcare sector company. Despite this deterioration in momentum, LLY maintains an Undervalued valuation verdict according to TickrTrends' current assessment.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is LLY stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), LLY is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is LLY's TickrTrends verdict?

LLY's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does LLY compare to other Healthcare stocks?

LLY ranks #11 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is LLY overbought or oversold?

LLY's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

LLY vs ADMA · LLY vs ALGN · LLY vs AMPH · LLY vs ANIP · LLY vs ASTH